NCT04939051 2026-03-18
Obeticholic Acid for Prevention in Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
12 trialsNCT06732388 2026-03-18
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT02521285 2025-10-23
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05745857 2023-02-27
SLURP
University Medical Center Groningen
Phase 2 Unknown
NCT01298999 2021-11-23
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
Columbia University
Phase 2 Completed
NCT02597712 2021-04-12
YF476 in Barrett's Esophagus
Trio Medicines Ltd.
Phase 2 Completed
NCT02018367 2021-01-14
Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma
Anandasabapathy, Sharmila, M.D.
Phase 2 Unknown
NCT03877601 2020-11-04
ESCEND
University Medical Center Groningen
Phase 2 Unknown
NCT02162758 2017-05-11
Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
Takeda
Phase 2 Terminated
NCT00217087 2015-12-24
Endoscopic Therapy of Early Cancer in Barretts Esophagus
Mayo Clinic
Phase 2 Completed
NCT01447927 2014-07-21
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus
National Cancer Institute (NCI)
Phase 2 Completed
NCT00474903 2014-07-02
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus
National Cancer Institute (NCI)
Phase 2 Completed